• ATS-9R: Expanding Adipocyte-Targeted Gene Delivery Horizons

  2026-07-01

  Explore how ATS-9R (Adipocyte-targeting sequence-9-arginine) enables next-generation, non-viral gene delivery to white adipose tissue. This article examines the unique mechanistic advances, application protocols, and strategic research implications that set ATS-9R apart for obesity-associated inflammation and metabolic disease research.

• Geneticin, G-418 Sulfate: Protocols and QC for Cell Selectio

  2026-07-01

  Geneticin, G-418 Sulfate (SKU A2513) provides reliable selection of genetically engineered cells expressing the neomycin resistance gene and supports antiviral research, notably for Dengue virus serotype 2. It is not suitable for experiments involving cell lines lacking aminoglycoside resistance, or for assays requiring a protein synthesis inhibitor with a different selectivity profile.

• ARCA Cy3 EGFP mRNA (5-moUTP): High-Efficiency Fluorescent mR

  2026-06-30

  ARCA Cy3 EGFP mRNA (5-moUTP) is a 5-methoxyuridine modified, Cy3-labeled mRNA enabling direct, quantitative mRNA delivery and localization studies in mammalian cells. This product achieves high translational efficiency and reduced immune activation, providing a robust benchmark for fluorescent mRNA imaging and transfection optimization.

• Dissecting A40926 Derivatives: Activity Against Gram-Positiv

  2026-06-30

  This study systematically prepared and characterized aglycone and pseudoaglycone derivatives of A40926, a potent glycopeptide and dalbavancin precursor, evaluating their antibacterial activity. The findings reveal structural determinants of efficacy against Gram-positive bacteria and Neisseria gonorrhoeae, guiding future research on glycopeptide optimization and resistance.

• G007-LK Tankyrase 1/2 Inhibitor: Advanced Strategies for β-C

  2026-06-29

  Explore how G007-LK, a potent tankyrase 1/2 inhibitor, enables advanced modulation of both the Wnt/β-catenin and Hippo/YAP signaling pathways in APC mutation colorectal cancer and hepatocellular carcinoma research. This article offers deep mechanistic insights and practical guidance beyond standard lab protocols.

• FCCP in Immunometabolic Research: From HIF Inhibition to TAM

  2026-06-29

  This article explores how FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) is transforming translational immunometabolic research. By bridging mechanistic insights on mitochondrial uncoupling, hypoxia pathway suppression, and tumor-associated macrophage (TAM) reprogramming, we provide a strategic guide for leveraging APExBIO's FCCP in next-generation metabolic regulation and cancer immunotherapy studies. Linking recent breakthroughs—such as 25-hydroxycholesterol-driven AMPK activation in TAMs—with validated experimental protocols, we outline how FCCP enables researchers to dissect and modulate the tumor microenvironment with unprecedented precision.

• Dovitinib (TKI-258): Advanced RTK Inhibition in Cancer Model

  2026-06-28

  Explore how Dovitinib (TKI-258) enables precision multitargeted RTK inhibition in advanced cancer research. This article reveals mechanistic depth and translational strategies distinct from prior content, including assay design insights inspired by stem cell differentiation advances.

• p53/PUMA-Mediated Synthetic Lethality via WRN Inhibition in

  2026-06-27

  This study elucidates how loss or inhibition of Werner (WRN) helicase selectively induces apoptosis in mismatch repair-deficient, microsatellite instability (MSI) colorectal cancer via the p53/PUMA pathway. The findings clarify the molecular rationale for targeting WRN in p53-wildtype MSI CRCs, strengthening the case for synthetic lethality-based therapies.

• Regulatory Cross-Talk in A40926 and Teicoplanin Biosynthesis

  2026-06-26

  The referenced study investigates the interplay of pathway-specific regulators in the biosynthesis of glycopeptide antibiotics A40926 and teicoplanin. By dissecting the functionality of key regulatory genes, it advances understanding of genetic control in antibiotic production, enabling targeted strategies for improving yields in research and industrial contexts.

• Tomivosertib: Advanced MNK1 Inhibitor Workflows in AML Resea

  2026-06-26

  Tomivosertib stands out as a highly selective MNK1/2 inhibitor, enabling precise modulation of the MNK-eIF4E signaling pathway in both cancer and neuronal research. This guide translates bench breakthroughs into actionable workflows—optimizing protocol design, troubleshooting, and combining Tomivosertib with other targeted strategies for maximal scientific insight.

• Paeoniflorin Modulates Tmem176b+ Macrophages in Liver I/R In

  2026-06-25

  This study demonstrates that paeoniflorin attenuates hepatic ischemia-reperfusion (I/R) injury by promoting the polarization of Tmem176b+ macrophages from pro-inflammatory to reparative phenotypes. Using single-cell RNA sequencing and targeted macrophage depletion, the work clarifies key cellular mechanisms and identifies new avenues for immune modulation in liver injury.

• ATS-9R: Precision Gene Silencing for Targeted Adipose Therap

  2026-06-25

  Explore ATS-9R (Adipocyte-targeting sequence-9-arginine) as a next-generation platform for adipocyte-specific, non-viral gene silencing. This article delves into the molecular mechanism, experimental best practices, and translational insights that set ATS-9R apart for metabolic disease research.

• Axitinib (AG 013736): Deep Profiling for Precision Angiogene

  2026-06-24

  Explore how Axitinib (AG 013736) enables next-generation angiogenesis inhibition assays and tumor growth studies with unmatched selectivity. This article reveals nuanced protocol guidance and practical insights not covered by standard guides.

• A23187, Free Acid: Precision Calcium Ionophore in Cell Resea

  2026-06-23

  A23187, free acid empowers researchers to dissect calcium-dependent signaling, apoptosis, and metabolic events with unmatched reproducibility. This article details advanced workflows, troubleshooting, and the transformative impact of in vitro drug response metrics, translating bench research into actionable protocols.

• Mouse Neutrophil Cell Isolation Kit: Enabling Next-Gen Immun

  2026-06-23

  Explore how the Mouse Neutrophil Cell Isolation Kit empowers advanced immunotherapy studies with high-purity, activation-free neutrophil isolation. Learn how this kit uniquely supports translational breakthroughs by bridging fundamental immunology and innovative nanovaccine technologies.

15916 records 1/1062 page Next 12345 下5页 Last page